vs
Cytek Biosciences, Inc.（CTKB）与OCTAVE SPECIALTY GROUP INC（OSG）财务数据对比。点击上方公司名可切换其他公司
OCTAVE SPECIALTY GROUP INC的季度营收约是Cytek Biosciences, Inc.的1.7倍（$104.2M vs $62.1M），OCTAVE SPECIALTY GROUP INC净利率更高（-6.6% vs -70.9%，领先64.4%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 8.1%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs 17.7%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
CTKB vs OSG — 直观对比
营收规模更大
OSG
是对方的1.7倍
$62.1M
营收增速更快
OSG
高出57.9%
8.1%
净利率更高
OSG
高出64.4%
-70.9%
两年增速更快
OSG
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $104.2M |
| 净利润 | $-44.1M | $-6.9M |
| 毛利率 | 52.9% | — |
| 营业利润率 | -9.0% | — |
| 净利率 | -70.9% | -6.6% |
| 营收同比 | 8.1% | 66.0% |
| 净利润同比 | -557.1% | — |
| 每股收益（稀释后） | — | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBOSG
| Q1 26 | — | $104.2M | ||
| Q4 25 | $62.1M | $66.9M | ||
| Q3 25 | $52.3M | $66.6M | ||
| Q2 25 | $45.6M | $55.0M | ||
| Q1 25 | $41.5M | $62.8M | ||
| Q4 24 | $57.5M | $65.2M | ||
| Q3 24 | $51.5M | $70.0M | ||
| Q2 24 | $46.6M | $51.0M |
净利润CTKBOSG
| Q1 26 | — | $-6.9M | ||
| Q4 25 | $-44.1M | $-29.7M | ||
| Q3 25 | $-5.5M | $-112.6M | ||
| Q2 25 | $-5.6M | $-72.7M | ||
| Q1 25 | $-11.4M | $-44.7M | ||
| Q4 24 | $9.6M | $-20.9M | ||
| Q3 24 | $941.0K | $-27.5M | ||
| Q2 24 | $-10.4M | $-750.0K |
毛利率CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — |
营业利润率CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | -9.0% | -76.7% | ||
| Q3 25 | -17.6% | -48.2% | ||
| Q2 25 | -23.3% | -41.8% | ||
| Q1 25 | -36.1% | -24.1% | ||
| Q4 24 | 5.2% | -55.5% | ||
| Q3 24 | -8.2% | -29.7% | ||
| Q2 24 | -18.3% | -28.9% |
净利率CTKBOSG
| Q1 26 | — | -6.6% | ||
| Q4 25 | -70.9% | -73.8% | ||
| Q3 25 | -10.5% | -169.1% | ||
| Q2 25 | -12.2% | -132.3% | ||
| Q1 25 | -27.5% | -71.3% | ||
| Q4 24 | 16.8% | -55.1% | ||
| Q3 24 | 1.8% | -39.3% | ||
| Q2 24 | -22.4% | -1.5% |
每股收益（稀释后）CTKBOSG
| Q1 26 | — | $-0.13 | ||
| Q4 25 | — | $-0.82 | ||
| Q3 25 | — | $-2.35 | ||
| Q2 25 | — | $-1.54 | ||
| Q1 25 | — | $-1.22 | ||
| Q4 24 | — | $-11.75 | ||
| Q3 24 | — | $-0.63 | ||
| Q2 24 | — | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | — |
| 总债务越低越好 | — | $117.1M |
| 股东权益账面价值 | $341.7M | $833.6M |
| 总资产 | $461.5M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | $90.9M | $146.4M | ||
| Q3 25 | $93.3M | $27.5M | ||
| Q2 25 | $75.5M | $22.5M | ||
| Q1 25 | $95.3M | $34.1M | ||
| Q4 24 | $98.7M | $157.2M | ||
| Q3 24 | $162.3M | $40.8M | ||
| Q2 24 | $177.9M | $14.6M |
总债务CTKBOSG
| Q1 26 | — | $117.1M | ||
| Q4 25 | — | $117.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $518.0M | ||
| Q2 24 | — | $515.0M |
股东权益CTKBOSG
| Q1 26 | — | $833.6M | ||
| Q4 25 | $341.7M | $715.8M | ||
| Q3 25 | $378.6M | $843.4M | ||
| Q2 25 | $377.6M | $859.8M | ||
| Q1 25 | $379.6M | $852.2M | ||
| Q4 24 | $395.7M | $798.4M | ||
| Q3 24 | $385.5M | $1.5B | ||
| Q2 24 | $389.1M | $1.4B |
总资产CTKBOSG
| Q1 26 | — | $2.3B | ||
| Q4 25 | $461.5M | $2.2B | ||
| Q3 25 | $494.9M | $2.1B | ||
| Q2 25 | $493.3M | $8.5B | ||
| Q1 25 | $482.6M | $8.3B | ||
| Q4 24 | $499.5M | $8.1B | ||
| Q3 24 | $491.2M | $9.3B | ||
| Q2 24 | $483.7M | $8.2B |
负债/权益比CTKBOSG
| Q1 26 | — | 0.14× | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | — |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | — |
| 自由现金流率自由现金流/营收 | -2.9% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | — |
8季度趋势，按日历期对齐
经营现金流CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $-52.3M | ||
| Q3 25 | $-3.9M | $-41.2M | ||
| Q2 25 | $108.0K | $2.1M | ||
| Q1 25 | $-125.0K | $-12.6M | ||
| Q4 24 | $2.0M | $762.0K | ||
| Q3 24 | $13.2M | $48.9M | ||
| Q2 24 | $6.2M | $20.4M |
自由现金流CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — |
自由现金流率CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — |
资本支出强度CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — |
现金转化率CTKBOSG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
